Renal involvement in pediatric inflammatory bowel disease

Czech version

Authors: Švábová Eva ¹; Bauer David ²; Gonsorčíková Lucie ²; Zieg Jakub ¹
Authors‘ workplace: Pediatrická klinika, 2. lékařská fakulta, Univerzita Karlova a FN Motol, Praha ¹; Pediatrická klinika, 1. lékařská fakulta, Univerzita Karlova a Fakultní Thomayerova nemocnice ²
Published in: Čes-slov Pediat 2023; 78 (6): 330-334.
Category: Comprehensive Report
doi: https://doi.org/10.55095/CSPediatrie2023/053

Overview

Incidence of inflammatory bowel diseases is rising worldwide, especially within the pediatric population. Except for bowel involvement, other organs may be affected in patients with inflammatory bowel disease. Extraintestinal manifestations usually involve joints, skin, bile ducts and eyes. However, another organ system which can be affected is the urinary tract, especially kidneys. The most common renal manifestations of inflammatory bowel diseases are nephrolithiasis and renal parenchymal diseases, such as interstitial nephritis, glomerulonephritis and amyloidosis. In this review, we focus on the spectrum of kidney involvement related to inflammatory bowel diseases.

Sources

1. Béres NJ, Kiss Z, Sztupinszki Z, et al. Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease. Dig Liver Dis 2017; 49(4): 378–387.

2. Benchimol EI, Fortinsky K J, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm. Bowel Dis 2011; 17(1): 423–439.

3. Sýkora J, Pomahačová R. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol 2018; 24(25): 2741–2763.

4. Mamula P, Markowitz JE. Inflammatory bowel disease in early childhood and adolescence: special consideration. Gastroenterol. Clin. North Am 2003; 32 (3): 967–95.

5. Jang HJ, Kang B, Choe BH. The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. Transl Pediatr 2019; 8 (1): 4.

6. Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am 2018; 44(4): 699–714.

7. van Hoeve K, Hoffman I. Renal manifestations in inflammatory bowel disease: a systematic review. J Gastroenterol 2022; 57(9): 619–629.

8. Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 2014; 9(2): 265–270.

9. Jang HM, Baek HS, Kim JE, et al. Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr 2018; 61(10): 327–331.

10. Mutalib M. Renal involvement in paediatric inflammatory bowel disease. Pediatr Nephrol 2021; 36(2): 279–285.

11. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12(30): 4819.

12. Ricart E, Sandborn WJ. Extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis 2003: 257–277.

13. Oikonomou K, Kapsoritakis A, Eleftheriadis T, et al. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011; 17(4): 1034–1045.

14. Gkentzis A, Kimuli M, Cartledge J, et al. Urolithiasis in inflammatory bowel disease and bariatric surgery. World J Nephrol 2016; 5(6): 538.

15. Stewart CS, Duncan SH, Cave DR. Oxalobacter formigenes and its role in oxalate metabolism in the human gut. FEMS Microbiol Lett 2004; 230(1): 1–7.

16. Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 2002; 168(3): 937–940.

17. Corica D, Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis 2015; 10(2): 226–235.

18. Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: A Swedish population-based cohort study. J Am Soc Nephrol 2021; 32(2): 411–423.

19. Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol 2002; 17(10): 863–866.

20. Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn’s disease. Int J Colorectal Dis 2005; 20(5): 463–465.

21. Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial. Lancet 2017; 389(10084): 2117–2127.

22. Velciov S, Gluhovschi G, Sporea I, et al. Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study. Rom J Intern Med 2001; 49(2): 113–20.

23. Marcus SB, Brown JB. Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008; 46(3): 338–341.

24. Waters AM, Zachos M, Herzenberg A, et al. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn‘s disease. Nat Clin Pract Nephrol 2008; 4(12): 693–697.

25. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001; 7(4): 295–300.

26. Tada Y, Ishihara S, Ito T, et al. Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn’s disease. Intern Med J 2013; 52(17): 1899–1902.

27. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008; 103(3): 776–787.

28. Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn’s disease. Am J Gastroenterol 2001; 96(7): 2107–2112.

29. Fernández-Nebro A, Ureña I, Irigoyen MV, García-Vicuña R. Anti-TNF-α for treatment of amyloidosis associated with Crohn’s disease. Gut 2006; 55(11): 1666–1667.

30. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn’s disease treated with infliximab. Inflamm Bowel Dis 2008; 14 (3): 431–432.

31. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheumatol 2005; 52(8): 2519–2520.

32. Boscá MM, Pérez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn’s disease: treatment with tumor necrosis factor inhibitor. Gut 2006; 55(2): 294–295.

33. Iizuka M, Konno S, Horie Y, et al. Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease. Gut 2006; 55(5): 744–745.

34. Gisbert JP, González-Lama Y, Maté J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13 (5): 629–38.

35. Elseviers MM, D’Haens G, Lerebours E, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol 2004; 61: 83–9.

36. Moss JG, Parry CM, Holt RC, McWilliam SJ. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res 2022; 27(1): 61.

37. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20(7): 1400–1406.

38. Nielsen H, Kemp E, Petersen LJ, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Arthritis Res Ther 2001; 3: 1.

39. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86(4): 242–251.

40. Neale TJ, Rüger BM, Macaulay H, et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995; 146: 1444–54.

41. Ota M, Iwai H, Imai K, et al. Acute tubulointerstitial nephritis associated with infliximab in a patient with Crohn’s disease. Intern Med 2016; 55: 1367–1370.

42. Yoo YJ, Chung SY, Gu DH, et al. A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn’s disease. Korean J Gastroenterol 2014; 63: 308–312.

43. Subhaharan D, Ramaswamy PK, et al. Vedolizumab-induced acute interstitial nephritis in ulcerative colitis. ACG Case Rep J 2022; 9(6).

44. Simpson N, Seenan JP, et al. Acute interstitial nephritis secondary to vedolizumab. BMJ Case Rep CP 2021; 14(11).

45. Bailly E, Von Tokarski F, et al. Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis 2018; 71(1): 142–145.